118618-46-5Relevant articles and documents
Design and synthesis of fused soluble epoxide hydrolase/peroxisome proliferator-activated receptor modulators
Bl?cher,Lamers,Wittmann,Diehl,Hanke,Merk,Steinhilber,Schubert-Zsilavecz,Kahnt,Proschak
, p. 1209 - 1216 (2016/07/06)
Metabolic syndrome (MetS) is a widespread, complex disease cluster which consists of hypertension, atherosclerosis, dyslipidaemia and type II diabetes. The treatment of MetS requires multiple pharmaceutical agents leading to complex polypharmacy. Multi-ta
Potent and selective proline derived dipeptidyl peptidase IV inhibitors
Edmondson, Scott D.,Mastracchio, Anthony,Beconi, Maria,Colwell Jr., Lawrence F.,Habulihaz, Bahanu,He, Huaibing,Kumar, Sanjeev,Leiting, Barbara,Lyons, Kathryn A.,Mao, Ann,Marsilio, Frank,Patel, Reshma A.,Wu, Joseph K.,Zhu, Lan,Thornberry, Nancy A.,Weber, Ann E.,Parmee, Emma R.
, p. 5151 - 5155 (2007/10/03)
In-house screening of the Merck sample collection identified proline derived homophenylalanine 3 as a DPP-IV inhibitor with modest potency (DPP-IV IC50 = 1.9 μM). Optimization of 3 led to compound 37, which is among the most potent and selectiv
1,2,3-Triazoles: Structural changes on two effective inhibitors of the prostaglandin synthesis in vitro
Biagi,Livi,Scartoni,Verugi
, p. 597 - 611 (2007/10/02)
-